Enliven Therapeutics (NASDAQ:ELVN) Now Covered by JPMorgan Chase & Co.

Analysts at JPMorgan Chase & Co. began coverage on shares of Enliven Therapeutics (NASDAQ:ELVN) in a research report issued to clients and investors on Thursday, Briefing.com reports. The brokerage set an “overweight” rating and a $75.00 price target on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential upside of 63.61% from the company’s current price.

A number of other equities research analysts have also weighed in on the company. Mizuho lifted their price objective on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. JonesTrading upped their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Finally, Stifel Nicolaus upped their price objective on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $75.00.

Enliven Therapeutics Trading Down 1.4%

Enliven Therapeutics stock opened at $45.84 on Thursday. The firm has a 50-day moving average of $55.48 and a 200-day moving average of $47.12. The firm has a market cap of $3.36 billion, a P/E ratio of -27.45 and a beta of 0.30. Enliven Therapeutics has a 1-year low of $14.78 and a 1-year high of $62.32.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). Research analysts forecast that Enliven Therapeutics will post -1.69 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Enliven Therapeutics news, Director Lori Kunkel sold 10,000 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the transaction, the director owned 41,884 shares in the company, valued at approximately $2,114,723.16. This represents a 19.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $50.35, for a total value of $303,006.30. Following the transaction, the chief financial officer directly owned 38,000 shares of the company’s stock, valued at $1,913,300. This represents a 13.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 186,849 shares of company stock valued at $11,038,275 over the last ninety days. Company insiders own 3.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ELVN. First Light Asset Management LLC grew its holdings in Enliven Therapeutics by 574.1% in the second quarter. First Light Asset Management LLC now owns 1,360,750 shares of the company’s stock worth $69,058,000 after purchasing an additional 1,158,883 shares during the period. Tidal Investments LLC lifted its holdings in shares of Enliven Therapeutics by 27.7% during the second quarter. Tidal Investments LLC now owns 60,694 shares of the company’s stock valued at $3,080,000 after purchasing an additional 13,179 shares during the last quarter. WINTON GROUP Ltd bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth approximately $228,000. Engineers Gate Manager LP bought a new stake in shares of Enliven Therapeutics in the 2nd quarter worth approximately $1,479,000. Finally, Squarepoint Ops LLC purchased a new stake in shares of Enliven Therapeutics in the 2nd quarter worth approximately $259,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.

Enliven’s pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.